Relizorb™ (immobilized lipase)

RELiZORB™ is a first-of-its kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase. RELiZORB is designed for use by adults on enteral tube feeding who have trouble breaking down and absorbing fats. RELiZORB is developed using Alcresta’s proprietary enzyme immobilization technology. The active ingredient in RELiZORB is the digestive enzyme lipase, attached to polymeric carriers together called iLipase™.

As the enteral tube feeding formula passes through RELiZORB, it makes contact with the iLipase, and the fat in the formula is broken down to its absorbable form (fatty acids and monoglycerides) prior to ingestion. The iLipase remains in the cartridge and does not become part of what is ingested. Relizorb has been shown to break down 90% of fats in enteral feeding tube formulas, including the most difficult to break down long-chain polyunsaturated fatty acids (LCPUFAs), such as docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and arachidonic acid (AA), which are critical for growth and development.

Over time, decreased fat absorption can lead to deficiencies in important fatty acids, such as omega-3. A balanced ratio of omega-3 to omega-6 fatty acids is beneficial in maintaining normal development and overall health.

RELiZORB was assigned to the B4105 HCPCS billing code effective Jan. 1, 2019 and has a CE mark (No. CE 649251).